Eli Lilly Cuts It Throat, Could The Stock Drop To $40?
by 24/7 Wall St
The New York Times hits Eli Lilly (LLY) almost daily with a new article on how the drug company dupped doctors and patients into thinking that its drug for schizophrenia was safe and did not have horrible side effect. The Times sums it up: "The original results showed that patients on Zyprexa, Lilly’s pill for schizophrenia, were 3.5 times as likely to experience high blood sugar levels as those taking a placebo"
The drug is 30% of Lilly's revenue at $4.2 billion in 2005.
For investors who like risky or distressed investments, Lilly represents an especially dangerout bet. Think of Merck's Vioxx suits with the possibility that Lilly does not haved a good defence.
Although Lilly's stock has dropped from $58 to $52 recently, it could go much, much lower. It has not been much below $50 since mid-2002, and that was for a brief period.
According to Morningstar, Lilly has $5 billion in debt. Its cash and equivalents cover that. Cash from operations for the last four quarters is about $3 billion.
Liability suits, if successful, can suck up Lilly's earnings fairly quickly. And that is the risk. It appears that there are several smoking guns for plantiff's attorney to take to court. And, the stock could get killed.
__________
Related BHI articles
- Eli Lilly is Picking On Schizophrenics
- Merck Wants Out of Pfizer's Shadow
__________
The New York Times hits Eli Lilly (LLY) almost daily with a new article on how the drug company dupped doctors and patients into thinking that its drug for schizophrenia was safe and did not have horrible side effect. The Times sums it up: "The original results showed that patients on Zyprexa, Lilly’s pill for schizophrenia, were 3.5 times as likely to experience high blood sugar levels as those taking a placebo"The drug is 30% of Lilly's revenue at $4.2 billion in 2005.
For investors who like risky or distressed investments, Lilly represents an especially dangerout bet. Think of Merck's Vioxx suits with the possibility that Lilly does not haved a good defence.
Although Lilly's stock has dropped from $58 to $52 recently, it could go much, much lower. It has not been much below $50 since mid-2002, and that was for a brief period.
According to Morningstar, Lilly has $5 billion in debt. Its cash and equivalents cover that. Cash from operations for the last four quarters is about $3 billion.
Liability suits, if successful, can suck up Lilly's earnings fairly quickly. And that is the risk. It appears that there are several smoking guns for plantiff's attorney to take to court. And, the stock could get killed.
__________
Related BHI articles
- Eli Lilly is Picking On Schizophrenics
- Merck Wants Out of Pfizer's Shadow
__________
posted by Nico at
8:23 AM
1 Comments:
At a glance,zyprexa was promoted 'off label' to uses that weren't FDA approved.This opens up a can of worms for patients like myself took it for PTSD for which it was ineffective and moreover gave me diabetes.
True,leaked documents don't convey the 'whole picture' but what is compelling is that zyprexa is the 7th some say 5th largest drug sell in the world and Eli Lilly's #1 drug sale by their own admission.
This is for a drug that won't get you "high" cost $2.50 a pill and only indicated for less than 1% of the population.
Hello! Somebody in Lilly land is pushing zyprexa hard-Daniel Haszard
Post a Comment
Subscribe to Post Comments [Atom]
<< Home